Antidiarrheal efficacy of a quinazolin CFTR inhibitor on human intestinal epithelial cell and in mouse model of cholera

Indian Journal of Pharmacology

Volumn 44, Issue 5, 2012, Pages 619-623

  Patanayindee, Jenvit ^a   Muanprasat, Chatchai ^a   Soodvilai, Sunhapas ^a   Chatsudthipong, Varanuj ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

CFTR; CFTR inhibitor; chloride secretion; cholera; secretory diarrhea

Indexed keywords

APIGENIN; CHOLERA TOXIN; FORSKOLIN; QUINAZOLINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHLORIDE CURRENT; CHOLERA; CYTOTOXICITY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE FLUID; MOUSE; NONHUMAN;

CFTR; CFTR INHIBITOR; CHLORIDE SECRETION; CHOLERA; SECRETORY DIARRHEA;

ANIMALS; ANTIDIARRHEALS; CELL LINE, TUMOR; CHOLERA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; MICE; MICE, INBRED ICR; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84866252138     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.100392     Document Type: Article

References (19)

1. .osek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003;81:197-204.
2. Boschi-Pinto C, Velebit L, Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ 2008;86:710-7.
3. Sanchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 2008;65:1347-60.
4. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003;111:931-43.
5. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004;363:223-33.
6. Chandrasekhar MR, Krishna BV, Patil AB. Changing characteristics of Vibrio cholerae: Emergence of multidrug resistance and non-O1, non-O139 serogroups. Southeast Asian J Trop Med Public Health 2008;39:1092-7.
7. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: Molecular basis and regulatory aspects. Annu Rev Physiol 2000;62:535-72.
8. Thiagarajah JR, Verkman AS. CFTR pharmacology and its role in intestinal fl uid secretion. Curr Opin Pharmacol 2003;3:594-9.
9. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79 Suppl 1:S23-45.
10. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. Thiazolidinone CFTR inhibitor identifi ed by high-throughput screening blocks cholera toxin-induced intestinal fl uid secretion. J Clin Invest 2002;110:1651-8.
11. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009;8:153-71.
12. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo effi cacy. J Gen Physiol 2004;124:125-37.
13. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001;281:C1734-42.
14. Wongsamitkul N, Sirianant L, Muanprasat C, Chatsudthipong V. A plant-derived hydrolysable tannin inhibits CFTR chloride channel: A potential treatment of diarrhea. Pharm Res 2010;27:490-7.
15. Field M, Fromm D, al-Awqati Q, Greenough WB 3rd. Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J Clin Invest 1972;51:796-804.
16. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev 1999;79 Suppl 1:S215-55.
17. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxininduced intestinal ion and fl uid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004;126:511-9.
18. Lohi H, Mäkelä S, Pulkkinen K, Höglund P, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2002;283:G567-75.
19. Strohmeier GR, Reppert SM, Lencer WI, Madara JL. The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem 1995;270:2387-94.